Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel
FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.
FDA finds no benefit in deterring intranasal abuse; final data not yet submitted to determine IV abuse deterrence.